Summit Therapeutics (SMMT) stock analysis for 2026: ivonescimab's PD-1/VEGF bispecific mechanism, the head-to-head win over Keytruda in lung cancer, the Akeso license structure, single-asset concentration risk, the China-to-global data translatability question, and Robert Duggan's outsized role — a qualitative framework for a clinical-stage biotech.
Biogen (BIIB) stock analysis for 2026. We evaluate Leqembi's actual prescription trajectory, the Spinraza revenue decline, Skyclarys rare disease growth, diranersen Phase 2 tau data, and whether the 55% bounce from $121 to $188 is justified.
SK Biopharmaceuticals (KOSPI 326030) 2026 outlook: XCOPRI (cenobamate) US prescription growth, direct-sales model economics, CNS pipeline depth, competitive position in epilepsy treatment, and what foreign investors need to know before buying a Korean biotech.
Análisis de Hanmi Pharmaceutical (128940) para 2026: pipeline GLP-1 obesidad, efpeglenatide Fase 3, plataforma Lapscovery, hitos licencia MSD, capitalización IFRS de I+D, comparativa Celltrion, guía inversión KRX para latinoamericanos.
Hanmi Pharmaceutical (128940) 2026 outlook: GLP-1 obesity pipeline, efpeglenatide Phase 3, MSD license milestones, Lapscovery platform, IFRS R&D capitalization risk, and KRX investing guide for global investors.
Amgen 2026 analysis: MariTide GLP-1 Phase 3 inflection, Horizon Therapeutics integration, biosimilar erosion of Prolia and Enbrel, CMS drug price negotiation risk, and how US investors should position.